Alan Burnett
Prosiectau fel Prif Ymchwiliwr
1 o 5
- Accuracy testing of the chromosomal aberration and gene mutation markers of the AML profiler (01.03.2011 - 31.07.2013)
- Acute myeloid leukaemia or high risk myelodysplastic syndrome multi-site randomised trial (27.02.2011 - 31.12.2011)
- Acute Myeoild Leukaemia Trial (AML 15) Trial Grant (01.07.2002 - 31.12.2009)
- AML 15 Trial Support Account (01.07.2002 - 31.07.2010)
- AML 16 A protocol for older patients with acute myeloid luekaemia and high risk myelodysplastic syndrome (01.12.2006 - 01.12.2011)
Prosiectau fel Cyd-Ymchwiliwr
1 o 2
- Cancer Genetics Biomedical Research Unit (31.03.2011 - 31.05.2015)
- CD200: A putative target of AML (01.12.2008 - 30.11.2011)
- Clinical Hubs for phase 1 of the Cancer Research UK stratified medicine programme (01.07.2011 - 30.09.2022)
- Identification of therapeutic targets in acute myeloid leukaemia expressing the mutant RAS oncogene (31.03.2010 - 31.03.2014)
- Investigation of the role of RAL dysregulation in myeloid leukaemia (01.11.2008 - 31.10.2011)
Thomson Reuters Deutschland GmbH
Zur Giesserei 2
D-76227 Karlsruhe | Germany